Robert Strauss
- Department of Medicine
Associate Professor
Research
Publications
-
Atypical Intramucosal Melanocytic Cell Proliferation in Colorectal Mucosa
Volume: 150 Page(s): S17 - S17
10/01/2018 Authors: Zhang B; Strauss R; Moran A; Zhang P; Xu X -
A Memorial Tribute to Horacio Jinich.
Gastroenterology Volume: 154 Page(s): 2009 - 2011
06/01/2018 Authors: Strauss RM; Hersh T -
A Phase 2B, Multicenter, Randomized, Placebo-Controlled Dose-Ranging Trial of Peficitinib, an Oral JAK Inhibitor, in Patients with Moderately-Severely Active UC
Volume: 23 Page(s): S8 - S8
02/01/2017 Authors: Sands B; Sandborn W; Feagan B; Lichtenstein G; Zhang H; Szapary P; Panes J; Vermeire S; Christopher OOB; Dewey J -
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology Volume: 145 Page(s): 1035 - 1044.e5
11/01/2013 Authors: Poordad F; Lawitz E; Reddy KR; Afdhal NH; Hzode C; Zeuzem S; Lee SS; Calleja JL; Brown RS; Craxi A -
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med Volume: 364 Page(s): 1195 - 1206
03/31/2011 Authors: Poordad F; McCone J; Bacon BR; Bruno S; Manns MP; Sulkowski MS; Jacobson IM; Reddy KR; Goodman ZD; Boparai N -
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Hepatology Volume: 46 Page(s): 971 - 981
10/01/2007 Authors: Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E -
Prospective analysis of sustained virologic response (SVR) to PEG-interferon (PEG IFN) alfa-2b and ribavirin treatment in Asian and Hispanic patients with chronic hepatitis C: Results from the WIN-R trial
Volume: 44 Page(s): 320A - 321A
10/01/2006 Authors: Freilich B; Hu K-Q; Jacobson I; Brown R; Afdhal N; Kwo P; Santoro J; Becker S; Wakil A; Pound D -
Prior HCV treatment experience and its relationship to sustained virologic response (SVR): An analysis of the Win-R study database, a US academic community based trial
Volume: 130 Page(s): A836 - A837
04/01/2006 Authors: Kwo P; Jacobson IM; Brown RS; Freilich B; Afdhal B; Santoro J; Becker S; Wakil A; Pound D; Godofsky E -
Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, a US community based trial
Volume: 42 Page(s): 749A - 749A
10/01/2005 Authors: Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo P; Santoro J; Becker S; Wakil A; Pound D; Godofsky E -
The target trial: Final results using 3.0 mu g/kg pegylated interferon alfa 2-b (Peg;Peg-intron (R)) plus ribavirin (RBV;rebetol (R)) for chronic hepatitis C patients who were non-responders (NR) and relapsers (R) to previous therapy.
Volume: 42 Page(s): 651A - 651A
10/01/2005 Authors: White C; Wentworth C; Malet P; Lee W; Cantu V; Orellana M; Strauss R